Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

OTHER 34NIH 8INDUSTRY 2OTHER_GOV 1NETWORK 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 6Sarcoma 2Gynecologic 2Plasma cell 1Lymphoid 1Head & Neck 1Gastrointestinal 1CNS 1

Conditions

Squamous Cell Carcinoma of Head and Neck 1Salivary Gland Neoplasms 1Head and Neck Neoplasms 1

Interventions

Cisplatin 53Radiotherapy 36Fluorouracil 16Paclitaxel 15Radiotherapy, Intensity-Modulated 14Docetaxel 12Cetuximab 12Carboplatin 12Platinum 6Immunohistochemistry 6Radiotherapy, Conformal 5Gene Expression Profiling 5Radiation 4Polymerase Chain Reaction 4Nimorazole 4Drug Therapy 4Chemotherapy, Adjuvant 41,2-diaminocyclohexaneplatinum II citrate 4durvalumab 3Taxes 3Magnetic Resonance Spectroscopy 3In Situ Hybridization, Fluorescence 3Gemcitabine 3Afatinib 3vandetanib 2pembrolizumab 2dehydroftorafur 2Surgical Procedures, Operative 2Specimen Handling 2Reverse Transcriptase Polymerase Chain Reaction 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NETWORK × Erlotinib Hydrochloride × Head & Neck × Clear all
NCT00079053 2023-08-04

Adjuvant Erlotinib After Completing Chemoradiotherapy in Locally Advanced Squamous Cell Carcinoma of the Head and Neck

Canadian Cancer Trials Group

Phase 1 Completed
19 enrolled
Head & Neck

Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms, Salivary Gland Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡